The CPGs most frequently affected by GVs were ATM in 6/206 (2.9%) families, BRCA2 in 5/206 (2.4%) families (identified in approaches 1 and 2), GBA1 in 4/206 (1.9%) families as well as EGFR, GJB2, and SDHA in 3/206 (1.5%) families each of the glioma cohort (Fig. 2a). This evidence concerns the gene BRCA2 and central nervous system cancer.